Jurgen Figys joined Crowell & Moring's Brussels office as an associate in April 2013. His practice focuses primarily upon intellectual property and life sciences.
Jurgen is one of the few lawyers in Belgium also to be trained as a biomedical scientist. He is therefore able to combine his scientific reasoning with his legal knowledge, a considerable asset in the technology-driven IP field.
Jurgen predominantly works with clients in the pharmaceutical and biotechnology industry.
He has particular experience in patent litigation with regard to invalidity, third-party opposition proceedings against counterfeit seizure, and preliminary injunction proceedings. His pre-contentious experience includes freedom-to-operate patent analysis and drafting protective letters.
Jurgen is also involved in a number of trademark cases, such as parallel import litigation (accelerated proceedings on the merits).
Within the life sciences and pharmaceutical industry, he advises clients on regulatory issues concerning, for example, supplementary protection certificates, medical devices, EU marketing authorizations (including the mutual recognition procedure), as well as GMP regulations. Jurgen also assists European clients to comply with FDA regulations.
Thanks to his scientific background, Jurgen is also able to advise clients on other regulatory issues with a technical angle. Over the last few years, Jurgen has developed an impressive, substantive knowledge of REACH through his work for a wide range of U.S. and EU-based clients (manufacturers of sports equipment, bags/clothing, as well as artificial turf pitches). In addition to providing legal and strategic advice on REACH compliance, Jurgen is able in particular to assist clients with their more science-driven submissions to the European Chemicals Agency (ECHA) (preliminary risk assessments of potential chemicals of concern, etc.).
Prior to joining Crowell & Moring, Jurgen worked for ten years at the Free University of Brussels as a Ph.D. student and as a director of successive scientific studies for the Belgian Ministry of Defense, performing research on cell metabolism, apoptosis and cancer physiology. The design of a non-natural linear constrained peptide library was one of the main achievements of his project.
Admitted to practice: Brussels
Speeches & Presentations
"De Minimis in Belgian Patent Law," I.R.D.I.
Authors: Kristof Roox and Jurgen Figys.
"Jouer avec les limites de l’usage off-label?" Le Journal du Médecin 2394, 39
(February 13, 2015).
Author: Jurgen Figys
"De exclusieve bevoegdheid van de rechtbank van koophandel en het hof van beroep te Brussel in het nieuwe Wetboek intellectuele eigendom (Boek XI van het WER)," RABG
Author: Jurgen Figys.
"Grenzen aan off-label gebruik?" [Limits to off-label use?], Artsenkrant 2392, 27
(January 30, 2014).
Author: Jurgen Figys.
Client Alerts & Newsletters
In the News